MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100095-PIP01-21-M01) and to the deferral

MHRA-100095-PIP01-21-M03

Scope of the Application

Active Substance(s)

DORAVIRINE

Condition(s)

Treatment of human immunodeficiency virus-1 (HIV-1) infection

Pharmaceutical Form(s)

Tablets; Granules

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Merck Sharp & Dohme (UK) Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Merck Sharp & Dohme (UK) Limited submitted to the licensing authority on 17/03/2023 17:38 GMT an application for a Modification

The procedure started on 19/05/2023 15:20 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

tto accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100095-PIP01-21-M03

Of 12/06/2023 09:02 BST

On the adopted decision for DORAVIRINE (MHRA-100095-PIP01-21-M03) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for DORAVIRINE, Tablets; Granules , ORAL USE .

This decision is addressed to Merck Sharp & Dohme (UK) Limited, 120 Moorgate, London, UNITED KINGDOM, EC2M 6UR

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of human immunodeficiency virus-1 (HIV-1) infection

2.2 Indication(s) targeted by the PIP:

Antiretroviral therapy, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in children aged from birth to 18 years

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Tablets Granules

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age appropriate oral solid dosage form.
Non-Clinical Studies	2	Study 2 Dose range-finding juvenile toxicity study. Study 3 Definitive juvenile toxicity study.
Clinical Studies	3	Study 4 Open-label two period trial to evaluate pharmacokinetic, safety, and activity, of doravirine and doravirine fixed dose combination (FDC) with lamivudine and tenofovir disoproxil fumarate in HIV-1 infected adolescents from 12 to less than 18 years of age weighing at least 35 kg. Study 5 Open-label pharmacokinetic with sentinel cohort, safety, and activity study of doravirine in HIV-1 paediatric patients who are at least 4 weeks and less than 12 years of age. Study 6 Study deleted in procedure MHRA-100095-PIP01-21-M01. Study 7 Open-label two period study to assess the pharmacokinetics and safety of doravirine in term neonates born to HIV infected mothers who are at risk of HIV-1 infection vertically transmitted. Study 8 Study deleted in procedure MHRA-100095-PIP01-21-M01. Study 9 Study deleted in procedure MHRA-100095-PIP01-21-M01.
Extrapolation, Modeling & Simulation Studies	1	Study 10 Modelling and simulation and extrapolation study of the use of doravirine in paediatric patients from birth to less than 18 years of age and

		of the use of FDC of DOR/3TC/TDF in children from 6 years to less than 18 years of age.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	30/11/2028
Deferral of one or more studies contained in the paediatric investigation plan:	Yes